Tharimmune Files $2B Mixed Securities Shelf
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Tharimmune files $2B mixed securities shelf
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy THAR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on THAR
About THAR
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tharimmune Approved as Super Validator on Canton Network
- Super Validator Role: Tharimmune has been approved as a super validator on the Canton Network, processing over 700,000 daily transactions with a monthly volume of $9 trillion, thereby enhancing its competitive edge in the digital asset space.
- Successful Fundraising: The company completed a direct offering worth approximately $55 million on January 23, 2026, issuing 1.80 million shares of common stock, with proceeds aimed at expanding its Canton digital asset strategy and general corporate purposes.
- Clinical Candidate Progress: TH104, Tharimmune's lead clinical candidate, has completed its Phase 1 trial and is ready for Phase 2, targeting ultrapotent opioid exposure and chronic pruritus in primary biliary cholangitis patients.
- Positive FDA Feedback: TH104 received constructive guidance from the FDA, planning to integrate specific technical elements to optimize its prophylactic program against ultrapotent opioids, showcasing its potential for military and chemical incident responders.
Continue Reading
Tharimmune Advances Digital Asset Strategy via Canton Network
- Super Validator Role: Tharimmune has been approved to operate as a Super Validator on the Canton Network, responsible for over 700,000 daily transactions totaling $9 trillion in monthly volume, thereby enhancing its influence and revenue potential in the digital asset space.
- Digital Asset Strategy: Since November 2025, Tharimmune has established a unique digital asset treasury strategy that drives institutional utility and adoption across capital markets through CC acquisition and Super Validator operations.
- Market Transparency Enhancement: The programmable privacy features of the Canton Network allow market participants to achieve instantaneous settlement while maintaining confidentiality of critical information, further solidifying Tharimmune's strategic position in the transformation of global financial infrastructure.
- Quarterly Research and Engagement: Tharimmune will provide in-depth quarterly research and community development news, fostering dialogue among ecosystem participants and enhancing its leadership position in the digital asset domain.
Continue Reading